Renalytix Plc
OTC: RTNXF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- James R. McCullough
- Employees
- 102
- Headquarters
- New York City, United States
- IPO year
- 2019
- Market cap
- $22.5M
- Website
- https://renalytix.com
Loading RTNXF…
Loading profile data…Frequently asked questions about RTNXF
What does Renalytix Plc (RTNXF) do?
Renalytix Plc specializes in developing artificial intelligence-driven in vitro diagnostic solutions for kidney diseases. Its flagship offering, KidneyIntelX, is a sophisticated diagnostic platform. This system leverages an AI-powered algorithm that integrates diverse data inputs, including validated blood-based biomarkers, an individual's inher...
Where does RTNXF trade?
Renalytix Plc (RTNXF) trades on the Other OTC.
What sector is RTNXF in?
Renalytix Plc (RTNXF) operates in the Healthcare sector, specifically in the Medical - Healthcare Information Services industry.
Who is the CEO of Renalytix Plc?
James R. McCullough is the chief executive officer of Renalytix Plc (RTNXF).
Where is Renalytix Plc headquartered?
Renalytix Plc is headquartered in United States.
Does RTNXF pay a dividend?
Renalytix Plc (RTNXF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did RTNXF go public?
Renalytix Plc (RTNXF) completed its initial public offering in 2019.